Baker Tilly Wealth Management LLC Sells 222 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Baker Tilly Wealth Management LLC cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 514 shares of the biopharmaceutical company’s stock after selling 222 shares during the period. Baker Tilly Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $366,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in REGN. First Hawaiian Bank lifted its stake in Regeneron Pharmaceuticals by 18.8% in the fourth quarter. First Hawaiian Bank now owns 2,995 shares of the biopharmaceutical company’s stock worth $2,133,000 after acquiring an additional 474 shares during the period. Range Financial Group LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $220,000. Diversified Trust Co lifted its position in shares of Regeneron Pharmaceuticals by 93.0% in the 4th quarter. Diversified Trust Co now owns 2,330 shares of the biopharmaceutical company’s stock worth $1,660,000 after purchasing an additional 1,123 shares during the period. Nordea Investment Management AB boosted its stake in shares of Regeneron Pharmaceuticals by 23.6% during the fourth quarter. Nordea Investment Management AB now owns 42,667 shares of the biopharmaceutical company’s stock valued at $30,160,000 after purchasing an additional 8,135 shares in the last quarter. Finally, RK Asset Management LLC increased its holdings in Regeneron Pharmaceuticals by 9.9% during the fourth quarter. RK Asset Management LLC now owns 9,989 shares of the biopharmaceutical company’s stock valued at $7,115,000 after buying an additional 896 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $696.88 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $691.00 and a twelve month high of $1,211.20. The company’s 50 day moving average is $751.44 and its 200 day moving average is $962.58. The company has a market cap of $76.58 billion, a PE ratio of 17.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.10.

Analyst Ratings Changes

Several analysts have issued reports on the company. Sanford C. Bernstein dropped their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Barclays reduced their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Finally, Evercore ISI reduced their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $1,037.33.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.